Review
doi: 10.1007/BF01720509.
Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy
Affiliations
- PMID: 2405924
- DOI: 10.1007/BF01720509
Item in Clipboard
Review
Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy
Blut.
1990 Feb.
Erratum in
- Blut 1990 Apr;60(4):259
Abstract
Chemotherapy remains the backbone of treatment in AML. Of all adult patients 65% go into remission and have a chance of longer survival and of even being cured. Among the responders, 25% can be cured by intensive and long-term chemotherapy. Since the effect of chemotherapy appears not to be limited to a special period of time, its antileukemic and curative potential could be further exploited by multiple-step chemotherapy combining double induction, intensified consolidation and long-term maintenance. Improved antimicrobial treatment and the use of hematopoietic growth factors may help making multiple-step chemotherapy practicable, thereby increasing the cure rate in AML.
Similar articles
-
Remission induction therapy: the more intensive the better?Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S41-4. doi: 10.1007/s002800100305. Cancer Chemother Pharmacol. 2001. PMID: 11587366
-
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.Haematologica. 2004 Aug;89(8):950-6. Haematologica. 2004. PMID: 15339678 Clinical Trial.
-
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.Br J Haematol. 1998 Apr;101(1):130-40. doi: 10.1046/j.1365-2141.1998.00677.x. Br J Haematol. 1998. PMID: 9576193 Clinical Trial.
-
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.Semin Oncol. 1994 Dec;21(6 Suppl 16):33-8. Semin Oncol. 1994. PMID: 7528449 Review.
-
[Current and new therapeutic strategies in acute myeloid leukemia].Gan To Kagaku Ryoho. 2005 Mar;32(3):292-6. Gan To Kagaku Ryoho. 2005. PMID: 15791811 Review. Japanese.
Cited by
-
Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.Ann Hematol. 1991 Apr;62(4):119-28. doi: 10.1007/BF01702925. Ann Hematol. 1991. PMID: 2031974 Review.
-
Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia.Ann Hematol. 1991 Feb-Mar;62(2-3):59-63. doi: 10.1007/BF01714901. Ann Hematol. 1991. PMID: 2031969 Clinical Trial.
-
Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.Ann Hematol. 1991 Oct;63(4):179-88. doi: 10.1007/BF01703440. Ann Hematol. 1991. PMID: 1932295 Review.
-
Factors associated with transfusion requirements during treatment for acute myelogenous leukemia.Ann Hematol. 1993 Oct;67(4):153-60. doi: 10.1007/BF01695861. Ann Hematol. 1993. PMID: 8218536 Clinical Trial.
-
Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells.J Cancer Res Clin Oncol. 1992;118(5):329-33. doi: 10.1007/BF01294435. J Cancer Res Clin Oncol. 1992. PMID: 1583063 Free PMC article.